STAAR Surgical Revenue and Competitors

Monrovia, CA USA

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • STAAR Surgical's estimated annual revenue is currently $153.1M per year.(i)
  • STAAR Surgical received $6.8M in venture funding in May 2010.
  • STAAR Surgical's estimated revenue per employee is $243,032

Employee Data

  • STAAR Surgical has 630 Employees.(i)
  • STAAR Surgical grew their employee count by 6% last year.

STAAR Surgical's People

NameTitleEmail/Phone
1
Chairman/CEOReveal Email/Phone
2
STAAR SURGICAL, VP, Global FinanceReveal Email/Phone
3
Chief Clinical, Regulatory and Medical Affairs OfficerReveal Email/Phone
4
Chief Clinical, Regulatory and Medical Affairs OfficerReveal Email/Phone
5
Chief Legal OfficerReveal Email/Phone
6
Chief Financial OfficerReveal Email/Phone
7
VP, Global Head Consumer and Product MarketingReveal Email/Phone
8
VP Global Distributor OperationsReveal Email/Phone
9
VP, Investor, Media Relations and Corporate DevelopmentReveal Email/Phone
10
VP, Global Clinical and Medical AffairsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$20.3M817%N/AN/A
#2
$8.5M346%N/AN/A
#3
$4.5M18-10%N/AN/A
#4
$8M32-6%N/AN/A
#5
$5.3M210%N/AN/A
#6
$54.2M2169%N/AN/A
#7
$12M48N/AN/AN/A
#8
$10M405%N/AN/A
#9
$30.1M12022%N/AN/A
#10
$14.1M562%N/AN/A
Add Company

What Is STAAR Surgical?

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye has been dedicated solely to ophthalmic surgery for over 30 years. The company offers the EVO Visian implantable Collamer® lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery is called an Implantable Collamer Lens or "ICL". Nearly 600,000 Visian ICLs have been implanted to date. It also provides minimally invasive intraocular lenses (IOLs), including foldable IOLs for use in minimally invasive cataract surgical procedures; aspheric IOLs that produce a clearer image than traditional spherical lenses; nanoFLEX IOL, a single piece Collamer aspheric optic; and Toric IOLs for cataract patients, as well as preloaded injectors for use in cataract surgery. In addition, the company sells surgical products, and other related instruments and devices, as well as injector parts; and manufactures AquaFlow devices for the treatment of glaucoma. It markets its products to health care providers, including surgical centers, hospitals, managed care providers, health organizations, group purchasing organizations, and government facilities primarily under the STAAR, Visian, Collamer, CentraFLOW, AquaPORT, nanoFLEX, nanoPOINT, Epiphany, and AquaFlow trademarks. The company sells products directly through its sales representatives in the United States, Canada, Japan, Germany, the United Kingdom, and Spain, as well as through independent distributors in approximately 60 countries. STAAR Surgical Company was founded in 1982 and is headquartered in Monrovia, California.

keywords:Biotechnology,Hardware,Hardware Peripherals,Healthcare,Medical Devices,Pharmaceuticals

N/A

Total Funding

630

Number of Employees

$153.1M

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

STAAR Surgical News

2022-04-20 - Why STAAR Surgical Stock Dropped 12% This Week

STAAR Surgical saw strong revenue, margin and net income growth in 2021. The drop is part of a longer trend with STAAR's shares down more than...

2022-04-20 - Why STAAR Surgical Stock Dropped 12% This Week

STAAR Surgical (NASDAQ: STAA), which specializes in implantable lenses for the eye, saw its shares drop 12% this week, according to data...

2022-04-19 - STAAR Surgical (STAA) Scheduled to Post Earnings on ...

STAAR Surgical has set its FY 2022 guidance at EPS.Individual that wish to listen to the company's earnings conference call can do so using this...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$344.2M74557%N/A

STAAR Surgical Funding

DateAmountRoundLead InvestorsReference
2007-12-18$5.0MUndisclosedArticle
2010-05-24$6.8MUndisclosedArticle